The agreement grants Sinopharm exclusive rights to distribute the MUSE system in China.
With the agreement renewal, Sinopharm has been granted up to two years to gain all necessary regulatory approval and two to four years exclusivity rights following regulatory approvals.
As a part of the agreement, Sinopharm will purchase a minimum of $17.6 million of MUSE and related projects within four years of regulatory approval.
More articles on gastroenterology:
Dr. Anton Decker to serve as Mercy Health Physicians’ president
Are gastroenterologists looking for new avenues to increase practice revenue? 10 statistics
5 gastroenterologists leading GI mega-practices
